Cornelia Kropf-Sanchen
Overview
Explore the profile of Cornelia Kropf-Sanchen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
137
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Welcker K, Jonigk D, Kropf-Sanchen C, Tufman A, Draube A, Stenzinger A, et al.
Pneumologie
. 2024 Dec;
79(1):16-24.
PMID: 39642922
Treatment perspectives for non-small cell lung cancer (NSCLC) have been significantly expanded by the integration of immune checkpoint inhibitors into multimodal therapy concepts. Currently, combined, immune checkpoint-inhibitor-based therapy concepts are...
2.
Webendorfer M, Heinzen S, Sibbert C, Lessmann M, Kropf-Sanchen C, Thomas M, et al.
Oncol Res Treat
. 2024 Dec;
48(3):142-147.
PMID: 39626649
No abstract available.
3.
Acker F, Klein A, Rasokat A, Eisert A, Kron A, Christopoulos P, et al.
Clin Lung Cancer
. 2024 Aug;
25(8):672-682.e5.
PMID: 39153867
Purpose: MET amplification is a common resistance mechanism to EGFR inhibition in EGFR-mutant non-small cell lung cancer (NSCLC). Several trials showed encouraging results with combined EGFR and MET inhibition (EGFRi/METi)....
4.
Kemper M, Soltani Germy P, Acker F, Luan J, Griesinger F, Tufman A, et al.
Oncol Res Treat
. 2024 Apr;
47(6):312-315.
PMID: 38574467
No abstract available.
5.
Acker F, Luan J, Soltani Germy P, Kemper M, Blasi M, Griesinger F, et al.
Oncol Res Treat
. 2024 Mar;
47(6):306-311.
PMID: 38527447
No abstract available.
6.
Deininger K, Raacke J, Yousefzadeh-Nowshahr E, Kropf-Sanchen C, Muehling B, Beer M, et al.
Nuklearmedizin
. 2023 Sep;
62(5):284-292.
PMID: 37696296
Aim: The aim of this study was to derive prognostic parameters from 2-[F]fluoro-2-deoxy-D-glucose ([F]FDG-PET/CT) in patients with low-risk NSCLC and determine their prognostic value. Methods: 81 (21 female, mean age...
7.
Bozorgmehr F, Muller A, Rawluk J, Sianidou M, Chung I, Kropf-Sanchen C
Lung Cancer
. 2023 Sep;
184:107340.
PMID: 37657237
Over the last years, the emergence of immune checkpoint inhibitors (ICI) has revolutionized the treatment of non-small cell lung cancer (NSCLC). Patients in a palliative setting with previously very poor...
8.
Maurer M, Staudacher J, Meyer R, Maurer I, Lazaridis L, Muther M, et al.
J Cancer Res Clin Oncol
. 2023 Jun;
149(12):10075-10084.
PMID: 37261525
Purpose: Modern, personalized treatment concepts in oncology require an interdisciplinary and multiprofessional collaboration. In addition to its relevance in patient care, interdisciplinary collaboration is also becoming increasingly important in clinical...
9.
Kersten J, Baumhardt M, Hartveg P, Hoyo L, Hull E, Imhof A, et al.
J Clin Med
. 2021 Sep;
10(17).
PMID: 34501230
(1) Background: Long COVID syndrome refers to long-term sequelae of the novel viral disease, which occur even in patients with initially mild disease courses. However, there is still little evidence...
10.
Kaemmerer H, Gorenflo M, Huscher D, Pittrow D, Apitz C, Baumgartner H, et al.
J Clin Med
. 2020 May;
9(5).
PMID: 32414075
Introduction: Pulmonary hypertension (PH) is a common complication in patients with congenital heart disease (CHD), aggravating the natural, post-operative, or post-interventional course of the underlying anomaly. The various CHDs differ...